Alexander Berg, PharmD, PhD, FCP
PharmD, North Dakota State University
PhD, Pharmaceutical Sciences, North Dakota State University, Fargo ND
Alexander (Al) Berg, PharmD, PhD, FCP, is Vice President, Operations at the Cognigen Division of Simulations Plus, Inc., with responsibility for divisional business operations and management of scientific and non-scientific staff. In addition to his operations role, Dr. Berg provides strategic consulting services in clinical pharmacology, drug development, and pharmacometrics.
Following a fellowship in Clinical Pharmacology at Mayo Clinic, Dr. Berg worked as both a clinical pharmacologist and pharmacometrician in the pharmaceutical industry. In these roles, he implemented clinical pharmacology and model-informed drug discovery and development strategies from pre-IND through NDA submission. He has experience in the development of both new chemical entities and generic drugs and has therapeutic area expertise in neurology, oncology, and infectious disease.
Immediately prior to joining Cognigen, Dr. Berg was a Scientific Director at the Critical Path Institute, supporting both the Duchenne Regulatory Science Consortium (D-RSC) and the Critical Path to TB-Drug Regimens (CPTR) Initiative, a partnership with the Bill and Melinda Gates Foundation. He continues to actively support and contribute to global health initiatives related to the development of new therapies to improve the treatment of tuberculosis.
Dr. Berg is a recipient of the McKeen Cattell Award from the American College of Clinical Pharmacology (ACCP), is an ACCP Fellow, and is a registered pharmacist in the State of Minnesota.
- Clinical Pharmacology
- Drug Development
Awards & Recognition
- Fellow, American College of Clinical Pharmacology
- Recipient of the McKeen Cattell Award from the American College of Clinical Pharmacology
- American College of Clinical Pharmacology
- International Society of Pharmacometrics
Application of clinical pharmacology and model-informed drug discovery and development (MID3) strategies to solve drug development challenges in global health